SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update

Aug 8, 2016

SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference

Aug 4, 2016

SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis

Aug 1, 2016

SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited

Jul 13, 2016

SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Jul 6, 2016

SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants

Jun 21, 2016

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Jun 20, 2016

SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections

Jun 20, 2016

SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016

Jun 10, 2016

SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors

Jun 8, 2016